NCT01878695

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement and also is available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. In the exercise physiology literature, both oral and injectable NAC have been shown to reduce fatigue and improve recovery from exertion which has interesting implications for exploring cancer-related fatigue. In terms of cancer cell biology, reactive oxygen species (ROS) may play an important role in the development and progression of breast cancer

Conditions

• Stage 0/1 Breast Cancer
• Post Biopsy
• Pre-surgery

Interventions

Type	Name	Description
DRUG	IV/oral n-acetylcysteine

Timeline

• Start date: 2012-07-26
• Primary completion: 2015-05-14
• Completion: 2015-05-14
• First posted: 2013-06-17
• Last updated: 2025-05-02

Locations

1 site across 1 country: United States